Novavax to Participate in Upcoming Investor Conferences
September 10 2020 - 07:00AM
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company
developing next-generation vaccines for serious infectious
diseases, today announced it will participate in five upcoming
investor conferences. A topic of discussion will be Novavax’
COVID-19 vaccine candidate, NVX-CoV2373.
Conference details are as follows:
Citi 15th Annual BioPharma Virtual
Conference
Date: |
September 10,
2020 |
Event: |
Investor meetings only |
H.C. Wainwright 22nd Annual Global
Investment Conference
Date: |
September 14,
2020 |
Time: |
9:30 a.m. U.S. Eastern Time (ET) |
Event: |
Corporate presentation and investor meetings |
Live Webcast: |
www.novavax.com, “Investors”/ “Events” |
Cantor Virtual Global Healthcare
Conference
Date: |
September 15,
2020 |
Time: |
11:20 a.m. U.S. Eastern Time (ET) |
Event: |
Fireside chat and investor meetings |
Live Webcast: |
www.novavax.com, “Investors”/ “Events” |
Morgan Stanley Virtual 18th Annual
Global Healthcare Conference
Date: |
September 16,
2020 |
Time: |
12:30 p.m. U.S. Eastern Time (ET) |
Event: |
Fireside chat and investor meetings |
Live Webcast: |
www.novavax.com, “Investors”/ “Events” |
Leerink CyberRx Series: Vaccine
Forum
Date: |
September 23,
2020 |
Time: |
9:00 a.m. U.S. Eastern Time (ET) |
Event: |
Fireside chat |
A replay of the presentations will also be
accessible under the “Investors/Events”
section www.novavax.com.
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage
biotechnology company that promotes improved health globally
through the discovery, development, and commercialization of
innovative vaccines to prevent serious infectious diseases. Novavax
is undergoing clinical trials for NVX-CoV2373, its vaccine
candidate against SARS-CoV-2, the virus that causes COVID-19.
NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all
primary objectives in its pivotal Phase 3 clinical trial in older
adults. Both vaccine candidates incorporate Novavax’ proprietary
saponin-based Matrix-M™ adjuvant in order to enhance the immune
response and stimulate high levels of neutralizing antibodies.
Novavax is a leading innovator of recombinant vaccines; its
proprietary recombinant technology platform combines the power and
speed of genetic engineering to efficiently produce highly
immunogenic nanoparticles in order to address urgent global health
needs.
For more information, visit www.novavax.com and
connect with us on Twitter and LinkedIn.
Contacts: InvestorsSilvia Taylor
and Erika Trahanir@novavax.com240-268-2022
MediaBrandzone/KOGS CommunicationEdna
Kaplankaplan@kogspr.com617-974-8659
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Novavax (NASDAQ:NVAX)
Historical Stock Chart
From Mar 2023 to Mar 2024